



**ADDENDUM TO THE  
TOXICOLOGICAL PROFILE FOR  
2-HEXANONE**

Agency for Toxic Substances and Disease Registry  
Division of Toxicology and Environmental Medicine  
Atlanta, GA 30333

April 2012

## CONTENTS

Background Statement .....	1
2. HEALTH EFFECTS .....	1
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE.....	1
2.2.1 Inhalation Exposure .....	1
2.2.1.4 Neurological Effects .....	2
2.2.1.2 Cancer .....	2
2.3 TOXICOKINETICS .....	2
2.3.3 Metabolism .....	2
2.5 BIOMARKERS OF EXPOSURE AND EFFECT .....	3
3. CHEMICAL AND PHYSICAL INFORMATION .....	3
4. PRODUCTION, IMPORT, USE, AND DISPOSAL .....	3
5. POTENTIAL FOR HUMAN EXPOSURE .....	3
5.3 ENVIRONMENTAL FATE.....	4
6. ANALYTICAL METHODS .....	4
7. REGULATIONS AND ADVISORIES .....	4
8. REFERENCES .....	5

## ADDENDUM FOR 2-Hexanone Supplement to the 1992 Toxicological Profile for 2-Hexanone

### Background Statement

*This addendum for 2-Hexanone supplements the Toxicological Profile for 2-Hexanone that was released in 1992.*

*Toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). CERCLA mandates that the Administrator of ATSDR prepare toxicological profiles on substances on the Priority List and that the profiles be revised “no less often than once every three years”. CERCLA further states that the Administrator will “establish and maintain inventory of literature, research, and studies on the health effects of toxic substances” [Title 42, Chapter 103, Subchapter I, § 9604 (i)(1)(B)].*

*The purpose of this addendum is to provide, to the public, other federal, state, and local agencies a non-peer reviewed supplement of the scientific data that was published in the open peer-reviewed literature since the release of the profile in 1992.*

*Chapter numbers in this addendum coincide with the toxicological profile for [2-Hexanone](#) (1992). This document should be used in conjunction with the profile. It does not replace it.*

## 2. HEALTH EFFECTS

### 2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE

#### 2.2.1 Inhalation Exposure

Many animal studies have been located regarding inhalation exposure to 2-hexanone, but some of these studies did not provide information on the purity of 2-hexanone. The usefulness of the data is limited because of confounding variables, which provided uncertainty regarding whether exposure was to pure 2-hexanone or to an uncertain extent of 2-hexanone in a chemical mixture.

***Hepatic Effects.*** In rats, inhalation exposure to 2-hexanone has been shown to induce certain isomers of cytochrome P-450 and increase in liver weight. (Nakajima et al. 1991).

***Gastrointestinal Effects.*** Potentiated cholestasis (arrest in bile flow) was observed in rats that inhaled 2-hexanone and methyl isobutyl ketone for 3 days, 4 hours/day (levels not

reported). It was determined that 2-hexanone was more potent in this effect than methyl isobutyl ketone (Duguay and Plaa, 1997). These investigators suggested that, although the mechanism of ketone-induced cholestasis is not known, the increased bile canalicular membrane cholesterol content and enhanced accumulation of newly synthesized cholesterol may be involved in the increased effects of ketones on cholestasis (Duguay and Plaa, 1997).

#### **2.2.1.4 Neurological Effects**

Since the Toxicological Profile for 2-hexanone was issued in 1992, some new animal studies have emerged concerning the neurological effects from exposure to 2-hexanone via inhalation. Elke et al., (1995) observed (in rats) that axonal atrophy is a potentially significant pathogenic event occurring in central and peripheral distal axonopathy.

#### **2.2.1.2 Cancer**

In order to assess the toxic and carcinogenic effects of 2-hexanone, F-344/N rats and B6C3F1 mice were exposed via inhalation to 2-hexanone at 0, 450, 900, or 1,800 ppm for 6 hours/day for 5 days/week for 2 years. These investigators observed a decrease in body weight of male rats that were exposed to 900 ppm and in female mice that were exposed to 1,800 ppm. The target organs in these animals appeared to be the kidney for rats and the liver for mice (Stout et al., 2008). There was a higher incidence of renal tubule hyperplasia as well as increases in adenoma and carcinoma at 1,800 ppm (Stout et al., 2008). The incidence of chronic severe progressive nephropathy may have resulted from the increases in the other parameters, such as renal tubule hyperplasia. Furthermore, these results indicate that adrenal medulla hyperplasia was increased at 1,800 ppm of exposure to 2-hexanone and that there was a positive trend for increases in benign and malignant tumors (Stout et al., 2008).

## **2.3 TOXICOKINETICS**

### **2.3.3 Metabolism**

By using n-hexane as a prototype substrate, it has been demonstrated in rats that skeletal muscle microsomes have low levels of extra hepatic xenobiotic metabolism (Crosbie et al., 1997). Metabolism of n-hexane to 1, 2, and 3-hexanol, and 2-hexanone has been demonstrated in cultured rat myoblasts (Crosbie et al., 1997).

## **2.5 BIOMARKERS OF EXPOSURE AND EFFECT**

When it is necessary to investigate biological markers of occupational exposure to solvents, it appears plausible to collect urine samples rather than blood samples, because urine collection is considered a non-invasive sampling method (Kawai et al., 2003). Furthermore, urine and blood measurements of 2-hexanone and its metabolites may not reflect an adequate indication of exposure to this substance, since 2-hexanone and its metabolites may also result from exposure to n-hexane. Therefore, it has been suggested that it is better to assay for the un-metabolized solvent or the parent compound as an exposure marker, because its urinary excretion is primarily a function of its physico-chemical properties and will not be influenced very much by the differences in the metabolic or bio-transformation capacity of an individual (Kawai et al., 2003). Rats that received i.p. injections of 2-hexanone for 4 days manifested biomarkers of effects that included increased liver weights and increased levels of certain isomers of cytochrome P-450 in comparison to their corresponding controls (Nakajima et al., 1991).

## **3. CHEMICAL AND PHYSICAL INFORMATION**

No updated data.

## **4. PRODUCTION, IMPORT, USE, AND DISPOSAL**

No updated data.

## **5. POTENTIAL FOR HUMAN EXPOSURE**

No updated data.

### **5.3 ENVIRONMENTAL FATE**

2-Hexanone was produced and used as an industrial solvent for many materials, including lacquers, resins, oils, nitrocellulose, acrylates, and vinyl and alkyl coatings. However, the chemical is no longer produced in the United States, and its uses are restricted. The environmental half life of the vapor phase of 2-hexanone is about 2 days; one reason is its reaction with photo-chemically produced hydroxyl radicals (HSDB, 2009).

## **6. ANALYTICAL METHODS**

No updated data.

## **7. REGULATIONS AND ADVISORIES**

Since 1992, the Occupational Safety and Health Administration (OSHA) has set a new Time Weighted Average (TVA) exposure limit of 100 ppm (i.e., 100 parts of 2-hexanone in 1 million parts of air) as an average level for a 40 hr work week. OSHA has set a Short Term Exposure Limit (STEL) of 10 ppm in which the air is measured over a 15 minute period unless noted otherwise (NIOSH Pocket Guide, 2009).

## 8. REFERENCES

Anderson H R, Neilson J B, Grandjean P. 2000. Toxicologic evidence of developmental neurotoxicity of environmental chemicals. *Toxicology* 144:121–127.

Carney R, Dardis C, Cullen W, et al. 2002. Early spatial memory deficit induced by 2,5 hexanedione in the rat. *Toxicol Lett*,128:107–115.

Crosbie SJ, Blain PG, Williams FM. 1997. An investigation into the role of rat skeletal muscle as a site for xenobiotic metabolism using microsomes and isolated cells. 16:138–145.

David RM, Bernard LG, Banton M, et al. 1999. The effect of repeated methyl iso-butyl ketone vapor exposure on schedule-controlled operant behavior in rats. *Neurotoxicology* 20:583–589.

Duguay A, Plaa GL CS. 1997. Altered cholesterol synthesis as a mechanism involved in methyl iso-butyl ketone-potentiated experimental cholestasis. *Toxicol Appl Pharmacol.* 147:281–288.

Duguay AB, Plaa GL CS. 1997. Ketone potentiation of intrahepatic cholestasis: effect of two aliphatic isomers. *J Toxicol Environ Health* 50:41–52.

Elke K, Bergerow J, Opperman H, et al. 1995. In-vitro quantitative structure-activity relationship assessment of pyrrole adducts production by Gamma-Diketone-forming neurotoxic solvents. *Toxicol In Vitro* 9:783–787.

Kawai T, Zhang Z-W, Takeuchi A, et al. 2003. Methyl iso-butyl ketone and methyl ethyl ketone in urine as biological markers of occupational exposure to these solvents at low levels. *Int Arch Occup Environ Health* 76:17–23.

Lo Pachin RM. 1998. Molecular mechanisms of hexcarbon induced axon atrophy. NIH

Nakajima T, Elovaara E, Park S. 1991. Immunochemical detection of cytochrome P450 isozymes induced in rat liver by n-hexane, 2-hexanone and acetonyl acetone. Arch Toxicol 65:542–547.

National Library of Medicine's Hazardous Substance Databank [HSDB], 2009. [HSDB Search](#)

NIOSH Pocket Guide to Chemical Hazards, Department of Health and Human Services, National Institute for Occupational Safety and Health, August 2009. [NIOSH Document: Pocket Guide to Chemical Hazards| CDC/NIOSH](#)

Noraberg J, Arlien-Soborg P. 2000. Neurotoxic interactions of industrially used ketones. Neurotoxicology 21:409–418.

Slikker W, Miller RK. 1994. Placental Metabolism and Transfer: Role in Developmental Toxicology. In: Kimmel CA, Buelke-Sam J (Eds.) Developmental Toxicology 2<sup>nd</sup> edn Raven Press, New York. Pp 245–283.

Stout MD, Herbert RA, Kissling GE, et al. 2008. Toxicity and carcinogenicity of methyl iso-butyl ketone in F344N rats and B6C3F1 mice following 2-year inhalation exposure.